Status: Recruiting
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma and other solid tumors.
Participants needed: 35
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Relay Therapeutics, Inc.Updated: Jul 2, 2026Locations: 9
Eligibility criteria
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. [+4]
Known activating KRAS, HRAS, or BRAF mutation or known alterations in other driv... [+3]